Forward Pharma A/S (NASDAQ: FWP) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Forward Pharma A/S to related businesses based off the strength of its dividends, profitability, valuation, earnings, analyst recommendations, institutional ownership and risk.


This table compares Forward Pharma A/S and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Forward Pharma A/S N/A -31.89% -30.50%
Forward Pharma A/S Competitors -4,472.14% -352.13% -43.32%

Volatility & Risk

Forward Pharma A/S has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Forward Pharma A/S’s competitors have a beta of 6.60, indicating that their average share price is 560% more volatile than the S&P 500.

Valuation & Earnings

This table compares Forward Pharma A/S and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Forward Pharma A/S N/A -$55.33 million -39.56
Forward Pharma A/S Competitors $467.45 million $168.91 million -6.57

Forward Pharma A/S’s competitors have higher revenue and earnings than Forward Pharma A/S. Forward Pharma A/S is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently the more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Forward Pharma A/S and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Forward Pharma A/S 0 2 1 0 2.33
Forward Pharma A/S Competitors 1362 4423 12178 310 2.63

Forward Pharma A/S currently has a consensus price target of $25.00, suggesting a potential downside of 10.98%. All “Bio Therapeutic Drugs” companies have a potential upside of 34.24%. Given Forward Pharma A/S’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Forward Pharma A/S has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

21.9% of Forward Pharma A/S shares are owned by institutional investors. Comparatively, 51.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


Forward Pharma A/S competitors beat Forward Pharma A/S on 9 of the 12 factors compared.

Forward Pharma A/S Company Profile

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis. The Company’s DMF formulation, FP187, employs over two methods, which improves the release of DMF by reducing the peaks of monomethyl fumarate (MMF) in the bloodstream while maintaining overall DMF exposure levels, which, in turn, controls DMF’s side effects. The Company has conducted a pre-clinical program and has completed several Phase I and Phase II clinical trials for the product FP187.

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with's FREE daily email newsletter.